Log in to save to my catalogue

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus...

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2490124386

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study

About this item

Full title

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2021-03, Vol.22 (3), p.370-380

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

SummaryBackgroundMelanoma lacks validated blood-based biomarkers for monitoring and predicting treatment efficacy. Cell-free circulating tumour DNA (ctDNA) is a promising biomarker; however, various detection methods have been used, and, to date, no large studies have examined the association between serial changes in ctDNA and survival after BRAF,...

Alternative Titles

Full title

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2490124386

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2490124386

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(20)30726-9

How to access this item